Cancellation of Regulation S Trading Line

19 December 2014

Lifeline Scientific, Inc.

("Lifeline" or "the Company")

Additional listing

Cancellation of Lifeline Scientific, Inc. Regulation S Trading Line

Lifeline Scientific (AIM: LSIC.L & LSI.L), the transplantation technology company, is pleased to announce that further to the regulatory announcements ("RIS") dated 3 December 2014 and 8 December 2014, the restricted Regulation S trading line (LSI.L ISIN USU529641008) "Reg S" will cease trading at 4:30 p.m. (UK time) on Friday 19 December 2014. Shareholders on the Reg S share register at close of business on the 19 December 2014 will have their holdings transferred to the unrestricted share register. From Monday 22 December 2014 all Lifeline shares will trade on the London Stock Exchange under TIDM LSIC, ISIN number US53223V1017.

 6,798,773 common shares on the restricted Reg S line will be switched to the unrestricted trading line with AIM delisting 6,798,773 restricted Reg S common shares under trading line (LSI.L ISIN USU529641008) on 19 December 2014. These shares will be admitted to trading on AIM under the unrestricted trading line TIDM LSIC, ISIN number US53223V1017.

For further information:

Lifeline Scientific, Inc. www.lifeline-scientific.com

David Kravitz, CEO Tel: +1 847 294 0300

Lisa Kieres, CFO Tel: +1 847 294 0300

Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500

Freddy Crossley (Corporate Finance)

Maisie Atkinson (Corporate Broking)

Wayne Slyfield (Corporate Broking)

CMS Cameron McKenna (Specialist US Securities and UK Counsel) Tel: +44 (0) 207 367 2700

Daniel Winterfeldt

Trish O'Donnell

Walbrook Tel: +44 (0)20 7933 8780 or [email protected] 

Paul McManus Mob: +44 (0)7980 541 893

Mike Wort Mob: +44 (0)7900 608 002

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product is the market-leading and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart and lung are in late stage pre-clinical development. For more information please visit www.lifeline-scientific.com

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to provide improved kidney preservation, evaluation and transport prior to transplantation. Today, it is widely recognised as the world's leading machine preservation device for kidneys. Employed by surgeons in over 160 leading transplant programmes in 27 countries worldwide, LifePorts have successfully preserved over 47,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com